Overview

Open-Label Safety Study of AXS-05 in Subjects With Depression

Status:
Completed
Trial end date:
2020-10-23
Target enrollment:
Participant gender:
Summary
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
Phase:
Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
Bupropion
Dextromethorphan